Moreover, the construct targeting murine IgE and CD300a was administered simultaneously with allergen challenge in murine models of PCA and experimental asthma, showing the capacity of abolishing the allergic-inflammatory response in both of them, and thus demonstrating that specific targeting of CD300a on mast cells could be an effective therapeutic approach to inhibit allergic reactions [122]. Here, CD300A is linked to asthma.